Rallybio Corp Form 8-K Summary
Business Context and Reporting Period
Rallybio Corporation (RLYB), a Delaware corporation, filed this Current Report on Form 8-K on November 28, 2022. The report details the partial exercise of an underwriters' option related to a public equity offering previously announced on November 10, 2022.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The primary financial event reported is a capital raise transaction:
- Additional Shares Sold: 803,654 shares of Common Stock.
- Price per Share: $6.00 (less underwriting discounts and commissions).
- Transaction Type: Partial exercise of an over-allotment option granted to underwriters.
Material Changes
The material change reported is the increase in the total number of shares sold in the offering due to the underwriters' partial exercise of their option. The initial offering consisted of 5,000,001 shares of Common Stock and pre-funded warrants for 3,333,388 shares. The additional 803,654 shares bring the total Common Stock sold in the offering to 5,803,655 shares.
Outlook and Management Commentary
The issuance and sale of the Additional Shares are expected to close on or about December 1, 2022, subject to customary closing conditions. The offering is conducted pursuant to an effective shelf registration statement on Form S-3. No specific guidance, risk factors, or unusual items beyond the standard closing conditions were detailed in this specific filing.
Investor Verification Checklist
- Verify the final closing date of the Additional Shares (expected December 1, 2022).
- Confirm the total gross proceeds from the full offering (initial shares plus additional shares) in subsequent filings.
- Review the underwriting discounts and commissions to determine net proceeds.
- Check for any dilution impact on existing shareholders from the total 5,803,655 shares issued.